Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Pharmacy benefit managers, insurance companies, and pharmacists debated the causes and potential impacts of the new proposal ...

MEXICO CITY—President Trump wants to deploy a blunt new tool to fight Mexican cartels that flood the U.S. with drugs, by ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

Failing to follow state and federal drug testing protocols has resulted in an $8.5 million settlement in the wrongful death ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

The parents of a woman born with sodium valproate syndrome say they have endured 'years of hell' as they take fight to ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs. Lilly said ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...